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Introduction
Synovial sarcoma (SS) is a high-grade soft tissue malignancy that 
disproportionately affects adolescents and young adults. The 
prognosis of SS patients with advanced disease remains poor, with 
an approximately 50% five-year survival rate (1, 2). The sarcoma 
fusions SS18-SSX1 and SS18-SSX2 are distinguished by unique 
associations with chromatin modifier complexes of opposite func-
tions, SWI/SNF-BAF and polycomb repressive complexes (PRC1 
and PRC2). The epigenetic deregulation of gene expression that 
results from SS18-SSX1/2 interactions is thought to drive SS patho-
genesis (3–5). We previously reported on the ability of SS18-SSX2 
to reprogram mesenchymal precursor cells and activate a signaling 
network that controls stem cell self-renewal and differentiation. 
In this network, we detected the constitutive expression of sever-
al fibroblast growth factors (FGFs) and their receptors (FGFRs), 
indicating the existence of FGF autocrine loops in SS cells (6, 7). 
We further showed that FGFR2, a direct target of SS18-SSX2, pro-
moted growth and expression of neural markers in mesenchymal 
precursor cells and SS cells (6). Other groups have described an 
active FGFR pathway that promoted SS cell growth (8).
FGFR signaling involves a large family of FGF ligands and four 
FGF receptors (FGFR1–4). It is one of the few pivotal pathways that 
control embryonic development, from early stages to mesoderm 
patterning and organogenesis (9, 10). It carries out these func-
tions by regulating the proliferation, survival, differentiation, and 
migration of progenitor cells. FGFR is believed to employ the same 
developmental functions to promote tumor initiation and progres-
sion in cancer (11). Aberrant FGFR signaling has been described in 
several human malignancies, including sarcomas, and attributed 
to activating mutations, amplifications, or fusions of FGFR genes. 
However, several studies have presented deregulated expression 
of FGFs and FGFRs as a driver of oncogenesis (10–16). Moreover, 
increased FGFR signaling has been shown to induce resistance to 
inhibitors of other oncogenic kinases (imatinib), as was demon-
strated in KIT-mutated gastrointestinal stromal tumors (17).
The E26 transformation specific (ETS) family of transcrip-
tion factors includes 28 members that share the ETS domain and 
bind to the core GGA(A/T) sequence. The PEA3 subset of the 
ETS family consists of 3 factors, ETV1 (ER81), ETV4 (Pea3), and 
ETV5 (ERM) (18). These factors play essential roles in embryonic 
development, including neurogenesis (19), spermatogenesis (20), 
lung branching (21), and limb bud formation (22). In these events, 
ETV4 and ETV5 were identified as transcriptional targets of FGFR 
signaling while simultaneously mediating FGFR target gene 
expression (9). ETV fusions were discovered in Ewing’s sarcoma 
(EWS-ETV1/4) and prostate cancer (TMPRSS2-ETV1/4/5) translo-
Synovial sarcoma is an aggressive malignancy with no effective treatments for patients with metastasis. The synovial 
sarcoma fusion SS18-SSX, which recruits the SWI/SNF-BAF chromatin remodeling and polycomb repressive complexes, 
results in epigenetic activation of FGF receptor (FGFR) signaling. In genetic FGFR-knockout models, culture, and xenograft 
synovial sarcoma models treated with the FGFR inhibitor BGJ398, we show that FGFR1, FGFR2, and FGFR3 were crucial for 
tumor growth. Transcriptome analyses of BGJ398-treated cells and histological and expression analyses of mouse and human 
synovial sarcoma tumors revealed prevalent expression of two ETS factors and FGFR targets, ETV4 and ETV5. We further 
demonstrate that ETV4 and ETV5 acted as drivers of synovial sarcoma growth, most likely through control of the cell cycle. 
Upon ETV4 and ETV5 knockdown, we observed a striking upregulation of DUX4 and its transcriptional targets that activate 
the zygotic genome and drive the atrophy program in facioscapulohumeral dystrophy patients. In addition to demonstrating 
the importance of inhibiting all three FGFRs, the current findings reveal potential nodes of attack for the cancer with the 
discovery of ETV4 and ETV5 as appropriate biomarkers and molecular targets, and activation of the embryonic DUX4 pathway 
as a promising approach to block synovial sarcoma tumors.
ETV4 and ETV5 drive synovial sarcoma through cell 
cycle and DUX4 embryonic pathway control
Joanna DeSalvo,1,2 Yuguang Ban,2,3 Luyuan Li,1,2 Xiaodian Sun,2 Zhijie Jiang,4 Darcy A. Kerr,5 Mahsa Khanlari,5 Maria Boulina,6 
Mario R. Capecchi,7 Juha M. Partanen,8 Lin Chen,9 Tadashi Kondo,10 David M. Ornitz,11 Jonathan C. Trent,1,2 and Josiane E. Eid1,2
1Department of Medicine, Division of Medical Oncology, 2Sylvester Comprehensive Cancer Center, and 3Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, 
USA. 4University of Miami Center for Computational Science, Coral Gables, Florida, USA. 5Department of Pathology and 6Analytical Imaging Core Facility, Diabetes Research Institute, University of Miami 
Miller School of Medicine, Miami, Florida, USA. 7Department of Human Genetics, Howard Hughes Medical Institute, University of Utah, Salt Lake City, Utah, USA. 8Faculty of Biological and Environmental 
Sciences, University of Helsinki, Helsinki, Finland. 9Center of Bone Metabolism and Repair, Research Institute of Surgery, Daping Hospital, Army Medical University, Chongqing, China. 10Division of Rare 
Cancer Research, National Cancer Center Research Institute, Tokyo, Japan. 11Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri, USA.
Conflict of interest: The authors have declared that no conflict of interest exists.
Copyright: © 2021, American Society for Clinical Investigation.
Submitted: July 1, 2020; Accepted: May 11, 2021; Published: July 1, 2021.
Reference information: J Clin Invest. 2021;131(13):e141908. 
https://doi.org/10.1172/JCI141908.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
J Clin Invest. 2021;131(13):e141908  https://doi.org/10.1172/JCI1419082
ure 2). As previously reported, tumors in the SM2 mice arise in the 
intercostal muscles near the cartilage-bone junction, and they are 
fully grown by 8 weeks of age (7). Based on these criteria, we ana-
lyzed tumor development in the SMF models at 10 weeks of age. 
In a group of 17 SM2 mice, tumors formed with 100% penetrance, 
with 3 tumors or more per mouse (Figure 1A, left graph). We found 
that deletion of 1 wild-type Fgfr allele decreased tumor incidence 
to 80% in 10 SMF1.HET mice, 67% in 12 SMF2.HET mice, and 
83% in 12 SMF3.HET mice. This was accompanied by a decrease 
in the average tumor number per mouse. Remarkably, knockout of 
2 Fgfr alleles led to substantial attenuation of tumor incidence and 
number in all 3 groups, as 35% of 20 SMF1.HO mice, 10% of 20 
SMF2.HO mice, and 35% of 23 SMF3.HO mice developed visible 
tumors (Figure 1A). The near-complete inhibition of tumor growth 
in the SMF2.HO mice implies that FGFR2 signaling is more dom-
inant in the SS model than signaling of the remaining two recep-
tors. However, immunohistochemical (IHC) analysis of 2 tumors 
isolated from SMF1,2,3.HO mice showed expression of FGFR1 
(Figure 1B), FGFR2 (Figure 1C), and FGFR3 (Figure 1D), suggest-
ing leakiness in the Fgfr-knockout models. For quantitative anal-
ysis of Fgfr expression, we measured Fgfr1,2,3 mRNAs in tumors 
excised from 2 mice belonging to each group among the SM2, 
SMF1.HO, SMF2.HET, and SMF3.HO groups. Use of SMF2.HET 
was due to paucity of SMF2.HO tumor tissues available for RNA 
extraction. Transcription of the Fgfr genes in the SMF tumor mod-
els was compared with their expression in corresponding inter-
costal tissues taken from 2 control, non–tumor-forming Myf5-cre 
mice. Quantitative reverse transcription PCR (RT-qPCR) analysis 
showed that Fgfr1 in the SM2 and SMF1.HO tumors was expressed 
at levels equivalent to those of control rib tissue, whereas levels 
of Fgfr2 transcripts were 240- and 220-fold higher in SM2 and 
SMF2.HET tumors, and those of Fgfr3 were 28- and 44-fold high-
er in SM2 and SMF3.HO tumors, compared with controls (Figure 
1E). The almost equivalent Fgfr expression between the SMF.HO/
HET and SM2 tumors likely reflects leakiness in the Fgfr-knockout 
models; it also supports the notion that FGFR expression is con-
comitant with SS tumor development.
In conclusion, results from the genetic Fgfr-knockout models 
clearly indicate that FGFR1, FGFR2, and FGFR3 are expressed in 
SS tumors, and they play a crucial role in SS development. They 
also revealed that complete loss of each FGFR is required for sig-
nificant inhibition of tumor formation. Interestingly, FGFR2 acti-
vation appeared to be exclusive to SS tumors, as we failed to detect 
measurable Fgfr2 mRNA in the control rib tissues.
FGFR inhibitor BGJ398 impedes SS tumor cell growth in vitro and 
in vivo. To verify the clinical significance of tumor suppression in 
the Fgfr-knockout mice, we asked whether pharmacological inhi-
bition of FGFR signaling in human SS cells would lead to similar 
effects. For this we chose BGJ398, a selective inhibitor of FGFR1, 
FGFR2, and FGFR3. BGJ398 was shown to be well tolerated and 
lacking toxicity in mice and humans (47–49). Two human SS cell 
lines, SYO-1 and HS-SY-II, which express the SS18-SSX2 and SS18-
SSX1 fusions, respectively, were treated with incremental doses 
of BGJ398 (5 to 5000 nM). The effect of BGJ398 on cell growth 
was measured after 2 days and 4 days of treatment. In a prolifer-
ation assay, the SYO-1 and HS-SY-II cells were highly sensitive to 
FGFR inhibition, and their growth was significantly decreased 
cations (18). In aggressive undifferentiated round cell sarcomas, 
ETV4 activation by the CIC-DUX4 (capicua–double homeobox 4) 
fusion is considered a driver of tumor metastasis (23–27). Studies 
in several malignancies, such as prostate, breast, lung, liver, and 
gastric cancers, have implicated ETV4 and ETV5 in their patho-
genesis (18, 28, 29). Moreover, ETV1, ETV4, and ETV5 activation 
is deemed a marker of poor prognosis (30, 31), and a causal factor 
of resistance to MAPK inhibitors in diverse cancers (32).
DUX4 (double homeobox 4) is an embryonic pioneer tran-
scription factor that drives the activation of the vertebrate zygotic 
genome (33–35). It is expressed within a narrow window of time, 
between the 2-cell and 4-cell cleavage stages, after which DUX4 
is epigenetically silenced and kept in a tight heterochromatic state 
in somatic tissues (36). In adults, DUX4 is expressed in testis and 
the thymus (37). The DUX4 gene is embedded in the 3.3-kb units 
of the D4Z4 subtelomeric macrosatellite repeats that normally 
include approximately 11 to 150 such units. Facioscapulohumeral 
dystrophy (FSHD) is an inherited muscular disorder attributed to 
misexpression of DUX4. Two epigenetic mechanisms are impli-
cated in DUX4 activation; one is contraction of the D4Z4 repeats 
to a number 10 or less in FSHD1, and the other is a mutated 
SMCHD1 (structural maintenance of chromosomes flexible hinge 
domain–containing protein 1) gene in FSHD2. Both mechanisms 
lead to chromatin relaxation and derepression of the DUX4 locus 
(35, 36). In FSHD patients, untimely activation of the embryonic 
program by DUX4 is thought to lead to muscle atrophy and death 
(38, 39). DUX4 was first linked to cancer as part of the transform-
ing CIC-DUX4 sarcoma translocation (27, 40, 41) and IGH fusions 
in B cell leukemia (42). A recent study revealed DUX4 as a promot-
er of immune evasion in several types of cancer (43).
In our quest to clarify the role of FGFR signaling in SS patho-
genesis, we uncovered an oncogenic axis that connects the FGFR 
pathway to the oncogenic ETS factors ETV4 and ETV5, and regu-
lation of the DUX4 embryonic program.
Results
FGFR1, FGFR2, and FGFR3 are required for SS tumor formation 
in mice. To elucidate the role of FGFR signaling in SS develop-
ment, we investigated the effect of FGFR loss on tumor formation 
in an established SS conditional mouse model, SSM2 Myf5-cre 
(SM2) (44). In this model, the SS18-SSX2 transgene is expressed 
in MYF5-positive myoblasts. The SM2 mice were generated as 
previously described (7). To create triple-mutant SSM2 Myf5-cre 
Fgfr(1,2,3) knockout mice, homozygous floxed alleles of FGFR1, 
FGFR2, and FGFR3 (Fgfr1fl/fl, Fgfr2fl/fl, and Fgfr3fl/fl) (45, 46) were 
mated with SSM2 and Myf5-cre transgenic mice, and then back-
crossed to Fgfr-floxed mice to obtain double mutants SSM2 
Fgfr(1,2,3)fl/fl and Myf5-cre Fgfr(1,2,3)fl/fl. The double mutants 
were mated to each other and to SSM2 transgenics to produce 
SSM2 Myf5-cre Fgfr(1,2,3)fl/wt (SMF1,2,3.HET) and SSM2 Myf5-cre 
Fgfr(1,2,3)fl/fl (SMF1,2,3.HO), with 1 or 2 Fgfr-floxed alleles, respec-
tively. The breeding scheme is delineated in Supplemental Figure 
1 (supplemental material available online with this article; https://
doi.org/10.1172/JCI141908DS1). Generation of all progeny fol-
lowed Mendelian inheritance and exhibited no sex bias. Impor-
tantly, double knockout of each of the three FGFRs did not affect 
the normal development of MYF5 myoblasts (Supplemental Fig-
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we designated 2 experimental groups, one of 11 and another of 8 
tumor-forming SM2 mice, aged 2 months, for similar treatments 
with BGJ398 (15 mg/kg) and vehicle, respectively. Following the 
protocol used for the SYO-1 xenografts, we observed that treat-
ment with BGJ398 resulted in a marked decrease in average tumor 
number (Figure 2E), as well as average tumor load (Figure 2F), 
per mouse. IHC analysis of 4 tumors from each group showed a 
50% decrease in Ki67-positive cells in the BGJ398-treated SM2 
mice compared with vehicle-treated mice (Figure 2G). We also 
observed that the SM2 mice maintained their weight and showed 
no overt signs of toxicity throughout the treatment period, thus 
supporting the safety of BGJ398 (Supplemental Figure 3).
starting with the lowest BGJ398 dose (Figure 2, A and B). To assess 
the effect of BGJ398 in vivo, SYO-1 cells were subcutaneously 
implanted in 8 immunodeficient (NU/J) mice. In this xenograft 
model, SS tumors usually develop with 100% efficiency. When 
the SYO-1–derived tumors reached a measurable size, 4 mice 
were treated with a daily oral dose (15 mg/kg) of BGJ398, and 
4 control mice were treated with vehicle solution, over a 13-day 
period. Importantly, tumors in all the BGJ398-treated mice failed 
to grow (Figure 2C). IHC analysis of the BGJ398-treated tumors 
revealed a 50% decrease in Ki67 positivity in comparison with the 
vehicle-treated tumors (Figure 2D). To determine whether FGFR 
inhibition leads to a similar growth arrest in natural SS tumors, 
Figure 1. SS tumor formation in 
FGFR-knockout mice. (A) Dot plots show 
number of tumors in the SM2, SMF1.HET, 
SMF1.HO, SMF2.HET, SMF2.HO, SMF3.HET, 
and SMF3.HO groups. Dots represent indi-
vidual mice. Crossbars show average number 
of tumors in each genetic model. Error bars 
indicate SEM. P values compare means of 
SMF.HET tumors versus SM2 (*P ≤ 0.00033) 
and means of SMF.HO tumors versus SMF.
HET (**P ≤ 0.0024). (B–D) IHC images show-
case FGFR1 (B), FGFR2 (C), and FGFR3 (D) 
expression in tumors that developed in SM2, 
SMF1.HO, SMF2.HO, and SMF3.HO mice. 
IgG served as background staining. Original 
magnification, ×40. (E) Box plot shows Fgfr1, 
Fgfr2, and Fgfr3 mRNA levels in the indicated 
tumor models compared with tissue derived 
from control mice. Each box represents RNA 
isolated from 2 mice in each group. The 12 
dots in each box indicate individual values 
normalized against Gapdh and plotted as 
fold change over control. Data are derived 
from 2 RT-qPCR experiments performed in 
6 replicates. P values compare mean Fgfr 
expression in each model against mean 
expression in control tissues. *P ≤ 0.00014. 
P values were calculated using 2-paired t 
test with P ≤ 0.05 considered as significant, 
throughout the paper.
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Figure 2. In vitro and in vivo effects of BGJ398 in SS cells and tumors. (A and B) Dose-response curves show effects of 2-day and 4-day BGJ398 treatments 
on SYO-1 (A) and HS-SY-II (B) cells relative to vehicle. Each point represents the average of 12 values derived from 2 independent experiments, each conducted 
in 6 replicates. Error bars indicate SEM. P values (*P ≤ 0.00079 in the SYO-1 curves; *P ≤ 0.00191 in the HS-SY-II curves) compare mean growth of BGJ398- and 
vehicle-treated cells at each point. (C) Box plot shows growth of BGJ398-treated and vehicle-treated (V) SYO-1 tumors. Dots represent individual tumors. 
Crossbars indicate average volumes. Error bars indicate SEM. P values compare mean volumes on days 3–14 after treatment with mean volume on day 1. *P ≤ 
0.0138; **P ≥ 0.064. (D) Box plot shows percentage of Ki67-positive cells in BGJ398-treated tumors and vehicle-treated tumors. Overlaid dots represent indi-
vidual fields counted in 4 tumors from each group; vehicle: 19 fields (2925 cells); BGJ398: 15 fields (1670 cells). Red crossbars indicate average percentages, and 
error bars indicate SEM. *P = 0.000194 was calculated by comparison of mean values of the 2 groups. (E) Dot plot shows tumor number per mouse in vehicle- 
and BGJ398-treated SM2 mice. (F) Plot shows individual tumor volumes in vehicle- and BGJ398-treated SM2 mice. Crossbars indicate average, and error bars 
indicate SEM. *P = 0.000937 (E) and *P = 0.0018 (F) compare means between the vehicle and BGJ398 groups. (G) Box plot shows percentage of Ki67-positive 
cells in BGJ398-treated and vehicle-treated SM2 tumors. Dots represent individual fields counted in 4 tumors from each group; vehicle: 19 fields (3527 cells); 
BGJ398: 21 fields (3244 cells). Crossbars indicate average percentages, and error bars indicate SEM. *P = 0.00341 compares means of both groups.
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Figure 3. BGJ398 inhibits ETV4 and ETV5 expression in SS cells. (A and B) Immunoblots show the effect of 50 nM and 500 nM BGJ398 on phospho-ERK1/2 
and phospho-AKT levels in SYO-1 (A) and HS-SY-II (B) cells at the indicated times. V, vehicle (DMSO). n = 2. (C) Functional categorization of the SYO-1 
transcriptome following a 24-hour BGJ398 treatment. (D) Heatmap illustrates the downregulation of FGFR pathway–related targets by BGJ398 in SYO-1 
cells; -1 and -2 represent duplicate samples. (E) RT-PCR of the indicated genes in SYO-1 (left panel) and HS-SY-II (right panel) cells treated with BGJ398 or 
vehicle. GAPDH served as input control. The PCR primers are described in Methods. (F) Immunoblot shows ETV4 and ETV5 levels in SYO-1 and HS-SY-II 
cells treated with BGJ398 or vehicle. Actin served as loading control. n = 2. (G) Immunoblots show ETV4 and ETV5 expression in 50 μg of SYO-1, HS-SY-II, 
CDS-S2, and CDS-X1 lysates. Two exposures of the ETV4 immunoblot are included. (H) Dot plot shows ETV4 and ETV5 mRNA levels in SS (SYO-1, HS-SY-II) 
relative to CDS-X1 cells. Dots represent independent values normalized against GAPDH and plotted as fold change. Data are derived from 2 RT-qPCR exper-
iments performed in triplicate. Crossbars indicate the mean. Error bars indicate SEM. P values (*P < 0.00001) compare ΔCt averages in CDS-X1, SYO-1, and 
HS-SY-II cells. (I and J) Bar graphs show CIC binding to ETV4 and ETV5 promoters in SYO-1 (I) and CDS-X1 (J) cells. Dots represent independent values from 2 
ChIP-qPCR experiments each conducted in triplicate. IgG served as background control. IgG binding and CIC binding were quantified as percentage of input 
chromatin. Error bars indicate SEM. P values (*P ≤ 0.0003 in SYO-1; *P < 0.00001 in CDS-X1) compare ΔCt averages of CIC antibody versus IgG.
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BGJ398 inhibits ERK signaling and ETV4/5 expression in SS cells. 
Following the growth results, we endeavored to identify the signal-
ing branch of the FGFR pathway regulated by BGJ398 in SS cells. 
We treated SYO-1 and HS-SY-II cells with 50 nM and 500 nM 
BGJ398 for 24 hours (before onset of cell death) and harvested the 
cells at 3 different time points within this period. The two BGJ398 
concentrations were chosen based on the dose range that induced 
40%–50% cell death (Figure 2, A and B). Lysate analysis showed 
a near-complete depletion of phosphorylated ERK1/2 as early as 4 
hours, with either dose of BGJ398, in both SS cell lines (Figure 3, 
A and B). The inhibitor failed to alter phospho-AKT levels (Figure 
3, A and B), thus indicating that BGJ398 abrogates the MAPK-ERK 
section of the FGFR pathway without affecting the PI3K pathway. 
We next sought to analyze the transcription program in SS cells 
following FGFR inhibition. To this end, total RNA was extracted 
from SYO-1 cells after a 24-hour treatment with 500 nM BGJ398 
and was subjected to RNA-Seq analysis. Five hundred nanomolar 
was chosen as a safe dose to induce optimal effect on transcrip-
tion in SS cells within 24 hours. The experiment was performed 
in duplicate. Transcripts that were significantly regulated (log2-
fold change ≥ 1.3) in the BGJ398-treated cells were selected and 
annotated. Functional categorization of the gene targets uncov-
ered mediators of mesenchymal lineage differentiation, with 
prevalence of neurogenic factors, reflecting the neuronal lineage 
often described in SS tumors. Furthermore, effectors of develop-
mental pathways, namely FGF, Wnt, NOTCH, HH (hedgehog), 
and BMP (bone morphogenetic protein), were also represented 
in the BGJ398–SYO-1 transcriptome (Figure 3C and Supplemen-
tal Table 1). However, the most striking finding in the RNA-Seq 
screen was a marked downregulation of four FGFR signal–related 
genes: Sprouty homolog 4 (SPRY4), dual-specificity phosphatase 
6 (DUSP6), ETV4, and ETV5 (Figure 3D and Supplemental Table 
1). SPRY4 and DUSP6 are known negative regulators of FGFR/
MAPK-ERK signaling, and ETV4 and ETV5 belong to the PEA3 
subfamily of ETS transcription factors. Decreased transcription 
of the four genes was validated by RT-PCR in SYO-1 and HS-SY-
II cells treated with 500 nM BGJ398 (Figure 3E). In addition, 
BGJ398 treatment led to a distinct attenuation of ETV4 and ETV5 
protein expression in both SS cell lines (Figure 3F).
Overexpression of ETV4 and ETV5 is thought to activate the 
malignant programs in the highly aggressive CIC-DUX4–driven 
sarcomas (CDS). To begin to understand ETV4/5 regulation in SS 
cells, we decided to compare expression of the two transcription 
factors in both sarcoma subtypes. Analysis of lysates with equal 
protein content derived from SYO-1, HS-SY-II, and two CDS cell 
lines, CDS-X1 (50) and CDS-S2 (51) showed that ETV4 was present 
at lower levels in the SS cells while ETV5 concentration was more 
comparable in the 2 sarcomas (Figure 3G). mRNA measurements 
in the 4 cell lines showed that ETV4 transcripts in SS cells ranged 
between 2% and 23% of those present in the CDS cells, while SS 
ETV5 RNAs ranged between 4% and 12% of ETV5 transcripts in 
the CDS cells (Figure 3H and Supplemental Figure 4A). In normal 
cells, the tumor suppressor CIC functions as a regulator of ERK 
signaling and a transcriptional repressor of ETV4 and ETV5 (52). It 
controls ETV4/5 by direct binding to CIC motifs in their promoter 
regions (53), and when it is mutated in cancer, inactivation of CIC 
leads to tumor metastasis secondary to ETV4/5 derepression (26, 
52). In CDS tumors, fusion of DUX4 C-terminal domain to CIC 
converts the latter from a repressor to a potent activator of ETV4/5, 
thus leading to an aggressive malignancy with poor clinical out-
come (23, 27, 40, 54). We immunoprecipitated CIC to compare its 
expression among the 4 sarcoma lines. The immunoprecipitates 
revealed significantly lower CIC levels in SS cells compared with 
CIC-DUX4 in CDS cells (Supplemental Figure 4B). Further anal-
ysis showed that ataxin1 (ATXN1) and ataxin1-like (ATXN1L), the 
two nuclear proteins that normally stabilize the CIC repressor com-
plex, were undetectable in SS cells (Supplemental Figure 4C and 
data not shown) (52). We next quantified CIC binding to its consen-
sus motifs (53) in ETV4 and ETV5 regulatory regions. We observed 
that in SYO-1 cells CIC occupied 6.5% and 5.4% of ETV4 and ETV5 
chromatin (Figure 3I), and by contrast, CIC-DUX4 was bound to 
41% and 24% of the respective genes in CDS-X1 cells (Figure 3J). 
This suggests that, as expected, the majority of active ETV4/5 loci 
in SS are not bound by CIC, and furthermore, they are derepressed 
through a mechanism different from CIC-DUX4.
Altogether, our findings have identified ETV4 and ETV5 as 
active targets downstream of BGJ398 and ERK1/2 in SS cells. Fur-
thermore, ETV4 and ETV5 appear to be activated in SS through a 
mechanism distinct from their upregulation in CDS cells.
FGFR depletion inhibits SS cell growth in vitro. To examine the 
effects of individual FGFR inhibition in SS cells, we expressed 
short hairpin lentiviral vectors targeting FGFR1 (shFGFR1), 
FGFR2 (shFGFR2), and FGFR3 (shFGFR3) in SYO-1 cells. First, 
we observed that depletion of one FGFR did not alter the expres-
sion of the two remaining receptors (Figure 4, A, C, and E, upper 
panels). Notably, we found that while ETV4 expression was mark-
edly diminished upon depletion of any one of the three receptors, 
ETV5 levels were decreased by FGFR2 knockdown alone (Figure 
4C, lower panel), and rather enhanced in shFGFR1 cells (Figure 
4A, lower panel) and shFGFR3 cells (Figure 4E, lower panel). Our 
third observation was the extensive cell death caused by the shF-
GFR vectors: 2 days after infection, 40%–60% of shFGFR1 (Fig-
ure 4B), shFGR2 (Figure 4D), and shFGFR3 (Figure 4F) cells were 
alive compared with cells transduced with control vector (non- 
target; TRC2), and 4 days after infection, only 6%–17% in all 3 
shFGFR groups survived (Figure 4, B, D, and F).
These findings confirm that signaling from FGFR1, 2, and 3 is 
required for SS cell growth, and that ETV4 and ETV5 are down-
stream of the FGFR pathway. The results also suggest that ETV4 
and ETV5 are differentially regulated by the individual members 
of the FGFR family. ETV4 and ETV5 are known targets as well as 
mediators of FGFR signaling in development (9, 30). They also 
have been linked to several human malignancies. Their dysregula-
tion upon FGFR inhibition in SS cells propelled us to further inves-
tigate their role in SS pathogenesis.
ETV4 and ETV5 are activated by SS18-SSX and overexpressed in 
SS tumors. We and others have reported on autocrine FGF signal-
ing in SS cells. We have also shown that upregulation of various 
FGF ligands and FGFRs, FGFR2 in particular, is induced by exog-
enous expression of SS18-SSX in mesenchymal precursor cells (6). 
To verify whether ETV4/5 expression is concurrent with active 
FGFR signaling in SS, we began by mining published gene expres-
sion arrays of SS18-SSX2–expressing C2C12 myoblasts and human 
mesenchymal stem cells (7), SS tumors from SSM2 Myf5-cre mice 
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(44), and 2 human SS tissue arrays (55, 56). This comprehensive 
analysis revealed prevalent expression of ETV4 and/or ETV5, 
several FGFs, and at least one FGFR, in all examined arrays (Sup-
plemental Table 2). Of particular interest, the SSM2 Myf5 tumors 
showed upregulation of Fgfr2 alone, whereas activation of all three 
FGFRs was detected by IHC and RT-qPCR in our models (Figure 
1, B–E). This discrepancy could be a matter of detection thresh-
old and choice of control tissue, as it corroborates our finding that 
Fgfr2 expression was highest (≥220-fold) among the three FGFRs 
(Figure 1E) in the SM2 tumors, and given the higher sensitivity 
of qPCR, we detected in addition Fgfr1 and Fgfr3 mRNAs in the 
tumors. To test whether ETV4/5 upregulation is dependent on 
SS18-SSX, we transduced C2C12 myoblasts with a retroviral SS18-
SSX2 vector and harvested the cells 2 days later. We found that 
ETV4 and ETV5 levels were significantly increased in the SS18-
SSX2–expressing cells (Figure 5A). To 
determine the frequency of ETV4/5 
overexpression in human SS, we ana-
lyzed tumor tissues from 10 SS patients. 
IHC revealed robust nuclear ETV4 and 
ETV5 signals in all 10 tumors (Figure 5, 
B–D, and Supplemental Figure 5A). Fur-
thermore, the SM2 and SMF1,2,3.HO 
tumors that displayed detectable levels 
of FGFR1,2,3 (Figure 1, B–E) were also 
positive for ETV4 and ETV5 expression 
(Figure 5, E–G). To gauge ETV4/5 sig-
nal intensity against an established pos-
itive SS marker, we examined represen-
tative human SS, SM2, and SMF tumors 
for TLE1 expression (57). As expected, 
all tumors tested displayed a strong nuclear TLE1 expression (Sup-
plemental Figure 5B). For better quantitation of ETV4 and ETV5 
expression in SS tumors, we measured ETV4/5 mRNA levels in 
the same tumors (SM2, SMF1.HO, SMF2.HET, and SMF3.HO) and 
compared them with levels in the Myf5-cre control tissues used in 
Figure 1E. RT-qPCR analysis showed that ETV4, ETV5, and Tle1 
were transcribed at significantly higher levels — 130- to 230-fold 
(Figure 5H), 12- to 32-fold (Figure 5I), and 23- to 38-fold (Figure 
5J), respectively — in the SMF tumors, compared with their expres-
sion in control tissues.
In summary, our findings show that ETV4 and ETV5 are down-
stream targets of the SS18-SSX oncoprotein and are persistently 
expressed in SS cells and tumors.
ETV4 and ETV5 are essential for SS cell growth and tumor ini-
tiation. Following the discovery of widespread ETV4 and ETV5 
Figure 4. Effect of FGFR depletion on SS cell 
growth. Immunoblots show FGFR1, FGFR2, 
FGFR3, ETV4, and ETV5 expression in SYO-1 
cells expressing shFGFR1 (A), shFGFR2 
(C), and shFGFR3 (E). Control is non-target 
(TRC2-PLKO.1) vector. shFs represent specific 
short hairpin FGFR-targeting vectors; -1 and 
-2 indicate different vectors. Actin served as 
loading control in all immunoblots. n = 2. The 
vertical lines in the ETV4, ETV5, and actin 
immunoblots designate nonconsecutive 
lanes of the same SDS-PAGE gels. Bar graphs 
show the effect of FGFR1 (B), FGFR2 (D), and 
FGFR3 (F) lentiviral depletion on SYO-1 cell 
growth on day 2 and day 4 after infection. 
Growth was measured by absorbance at 
570 nm. The 10 overlaid dots in each graph 
represent independent values from 2 
sulforhodamine B (SRB) assays conducted 
in 5 replicates each. Error bars indicate SEM. 
P values using paired t test compare mean 
absorbance in each shF group against mean 
absorbance in the control vector (TRC2) 
group. *P < 0.00001 in all graphs. ANOVA F 
ratios and corresponding P values shown on 
top of each graph demonstrate significant 
variation of means among the 3 groups on 
each day.
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Figure 5. ETV4 and ETV5 expression in SS tumors. (A) Immunoblot shows ETV4 and ETV5 levels in SS18-SSX2–expressing C2C12 myoblasts. Vector is 
backbone control vector (POZ; see Supplemental Methods). SS18-SSX2 was visualized with anti-FLAG antibody. Actin served as loading control. (B–D) 
ETV4 and ETV5 IHC staining in tumors resected from two SS patients. Scale bars on the inset images: 50 μm; all other scale bars: 500 μm. (E–G) Repre-
sentative images of ETV4 and ETV5 expression in tumors derived from SM2, SMF1.HO, SMF2.HO, and SMF3.HO mice. Scale bars: 20 μm. (H–J) Box plots 
show fold expression of ETV4 (H), ETV5 (I), and Tle1 (J) in the indicated tumor models over tissue derived from control mice. Two mice in each group were 
used for RNA isolation. The 12 overlaid dots in each box indicate individual values normalized against Gapdh and plotted as fold change over control. Data 
are derived from 2 RT-qPCR experiments performed in 6 replicates. Red crossbars indicate the mean. Error bars indicate SEM. P values compare average 
expression in each model against average expression in control tissues. *P < 0.00001; **P ≤ 0.00065; ***P ≤ 0.0019. ANOVA F ratios and corresponding  
P values shown on top demonstrate significant variation of means among the 4 groups in each plot.
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stantial depletion of ETV4 (shETV4-1,2; shETV4-A,B) and ETV5 
(shETV5-1,2; shETV5-A,B) in the SYO-1 (Figure 6A) and HS-SY-II 
(Figure 6B) SS cells. We observed that suppression of either ETV4 
or ETV5 led to significant inhibition of SS cell proliferation (Figure 
expression in SS, we wished to investigate the extent of their 
contribution to SS pathogenesis. We addressed this question by 
using short hairpin lentiviral vectors that specifically target each 
transcription factor. We found 4 such vectors that resulted in sub-
Figure 6. Effect of ETV4 and ETV5 
inhibition on SS cell and tumor growth. 
(A and B) Immunoblots show ETV4 
and ETV5 depletion in SYO-1 (A) and 
HS-SY-II (B) cells. shETV4-1, -2, -A, 
and -B and shETV5-1, -2, -A, and -B 
designate the lentiviral vectors used for 
specific knockdown of ETV4 and ETV5, 
respectively. Control is non-target vector 
(TRC2-PLKO.1). Dividing lines indicate 
noncontiguous lanes of the same SDS-
PAGE gels. (C and D) Bar graphs show 
the effects of ETV4 and ETV5 lentiviral 
depletion on SYO-1 (C) and HS-SY-II (D) 
cell growth. Growth was measured by 
absorbance at 570 nm. The 8 dots in each 
graph represent independent values from 
2 SRB assays conducted in 4 replicates 
each. Error bars indicate SEM. P values 
compare mean absorbance in shETV 
groups against mean absorbance in the 
control vector (TRC2) group. *P < 0.00001 
in both graphs. (E) Representative digital 
image of SS sarcospheres. (F and G) 
Dot plots show numbers of spheroids 
formed by SYO-1 (F) and HS-SY-II (G) 
cells expressing shETV4 and shETV5. 
Dots represent individual values derived 
from 2 independent assays performed in 
triplicate. Crossbars indicate the mean, 
and error bars indicate SEM. P values 
were measured by comparison of the 
average of each experimental group 
with that of the control (TRC2) group. *P 
range: 0.0318–0.0058 in SYO-1; *P range: 
0.018–0.001 in HS-SY-II. (H) Immunoblot 
illustrates specific knockdown of ETV4 
and ETV5 in SYO-1 cells transduced with 
shETV4-2 and shETV5-2 and implanted 
in NU/J mice. (I) Graph shows the total 
number of mice that developed tumors 
in each group, 3 months after injec-
tion. Actin served as loading control in 
all immunoblots. ANOVA F ratios and 
corresponding P values shown on top 
demonstrate significant variation of 
means among the 5 groups in each plot.
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Together, these data implicate ETV4 and ETV5 as pervasive 
promoters of cell cycle progression in SS cells. Moreover, it appears 
that the two factors impose a state of repressed chromatin in SS cells, 
including silencing of the zygotic program controlled by DUX4.
Convergence of ETV4/5 and DUX4 in SS cells. To further exam-
ine the role of ETV4/5 in cell cycle progression, we expressed 
shETV4-2 and shETV5-2 vectors in SYO-1 and HS-SY-II cells. 
Lysate analysis showed a significant attenuation in the levels of 
the cell cycle master controller E2F1 in both cell lines. Interesting-
ly, while E2F1 was decreased upon ETV4 and ETV5 depletion in 
HS-SY-II cells, we repeatedly observed that in SYO-1 cells, E2F1 
was affected by shETV5 alone (Figure 9A). Notably, levels of the 
cyclin-dependent kinase inhibitor CDKN1A (p21), the growth 
suppressor EGR1, and FOS polypeptides (detected by an antibody 
that recognizes c-FOS, FOSB, FOSL1, and FOSL2) were increased 
after ETV4 and/or ETV5 loss in both cell lines (Figure 9A). The 
next question we addressed was whether DUX4 upregulation con-
tributed to the cell cycle arrest that resulted from ETV4/5 knock-
down. To this end we performed combined infections whereby we 
transduced SYO-1 cells with equal titers of shETV5-2 and 1 of 2 
shDUX4 lentiviral vectors (shDUX4-1, shDUX4-2). In this exper-
iment we observed that infection with full shETV5-2 titer, or a 
mixture of half shETV5 titer and half control titer, led to increased 
DUX4 protein levels and severe growth arrest, in comparison with 
SYO-1 cells that were infected with a full titer of control vector. 
The latter group were almost devoid of DUX4 (lanes 1–3 in Fig-
ure 9, B and C). When shETV5 and shDUX4 were coexpressed 
at half titer each, we observed a significant rescue of the growth 
arrest phenotype. This was accompanied by a measurable deple-
tion of DUX4 (lanes 4 and 5 in Figure 9, B and C). Importantly, 
levels of ETV5 depletion in all 4 shETV5 groups included in this 
experiment were unchanged (Figure 9B). These data support the 
notion that activated DUX4 contributes to the proliferation arrest 
induced by shETV4/5. To analyze the direct effects of DUX4 acti-
vation in SS cells, we transduced SYO-1 and HS-SY-II cells with 
a doxycycline-inducible DUX4 expression vector (58). DUX4 
induction led to extensive cell death in both lines (Figure 9, D and 
E). RT-PCR analysis of RNA purified from DUX4-expressing SYO-
1 cells 16–24 hours after induction (harvested before extensive 
cell death) confirmed the upregulation of known DUX4 targets, 
including ZSCAN4, MBD3L3, KDM4E, and CCNA1. In addition, 
transcripts of CDKN1A, EGR1, and FOS family members were 
upregulated in the DUX4-expressing cells compared with unin-
duced cells (Figure 9F). We found that the transcriptional activa-
tion of the four genes was accompanied by significant elevation 
in the levels of their encoded proteins in DUX4-expressing SYO-1 
and HS-SY-II cells (Figure 9G). By contrast, DUX4 expression 
failed to alter E2F1 and SS18-SSX levels (Supplemental Figure 8), 
suggesting that DUX4 acts downstream of both proteins in SS cells. 
With these results we conclude that upregulation of the growth 
controllers (CDKN1A, EGR1, FOS) seen in the shETV4/5 cells is 
most likely driven by active DUX4. CDKN1A and EGR1 activation 
by DUX4 was previously reported (59, 60), and both growth sup-
pressors have been implicated in mediating the DUX4-dependent 
atrophy in FSHD muscles.
Genomic ETV4/5 interactions in SS cells. The majority of 301 cell 
cycle– and DNA repair–related genes identified in the shETV4/5 
6, C and D). Furthermore, individual loss of either ETV4 or ETV5 
impeded the ability of SYO-1 and HS-SY-II cells to form sarco-
spheres in serum-free culture media (Figure 6, E–G), implying that 
both factors are required for the maintenance of SS-initiating cells 
in vitro. To substantiate this finding in vivo, we subcutaneously 
implanted SYO-1 cells in immunodeficient mice, 24 hours after 
their transduction with the non-target (control), shETV4-2, and 
shETV5-2 vectors. The 24-hour time point was chosen to avoid 
injection of dying shETV-infected cells. We confirmed by immu-
noblotting the specific depletion of ETV4 and ETV5 in the injected 
cells (Figure 6H). This experiment was conducted in 2 parts, with 
5 mice per group in each part, hence a total of 10 mice per group. 
We monitored the mice for tumor growth over a 90-day period. At 
the end of the 3 months, all 10 control mice and 1 shETV4 mouse 
had formed large SS tumors, while none of the shETV5 mice devel-
oped a visible mass at the injected site (Figure 6I).
Altogether, the functional results establish ETV4 and ETV5 
as drivers of SS growth, and, importantly, both factors seem to be 
required for this task.
ETV4 and ETV5 control the cell cycle, chromatin structure, 
and the DUX4 zygotic program in SS cells. To better understand 
ETV4/5-mediated effects on SS growth, we proceeded to identi-
fy the transcriptional programs controlled by ETV4/5 in SS cells. 
Total RNA was purified from SYO-1 cells, 24 hours after trans-
duction with control, shETV4-2, and shETV5-2 vectors, then was 
analyzed by RNA-Seq. This experiment was conducted in dupli-
cate. Gene annotation and functional categorization of differen-
tially regulated transcripts (Supplemental Table 3) yielded striking 
results: a massive downregulation (301 genes) of cell cycle– and 
DNA repair–related genes in ETV4-depleted (shETV4-2a,2b) and 
ETV5-depleted (shETV5-2a,2b) cells (Figure 7A and Supplemental 
Figure 6). The downregulated genes encoded mediators of early 
and late cell cycle progression, and checkpoint control, including 
E2F1/2, FOXM1, cyclins, and CDKs (cyclin-dependent kinases). In 
addition to ETV4 and ETV5 that were specifically depleted by their 
respective targeting vectors, we identified a group of 76 genes rep-
resenting transcription factors that were differentially expressed 
in the shETV4- and/or shETV5-transduced cells. Worthy of note 
were the growth and differentiation regulators EGR1 and EGR2 
(early growth response 1 and 2) and several members of the AP1 
family, such as JUN, FOS, FOSB, FOSL1, and FOSL2, all activated 
upon ETV4 and ETV5 loss (Figure 7B and Supplemental Figure 7). 
A third category of interest included 135 genes of chromatin struc-
ture modulators (Figure 7C and Supplemental Figure 7). Functional 
classification of this group revealed a noticeable pattern of chroma-
tin opening illustrated by downregulation of heterochromatin-pro-
moting chaperones and DNA and histone methyltransferases 
(DNMT1/3B, UHRF1, CBX1/5, SUV39H1/2, EZH2, CHAF1A/B) 
and a contrasting upregulation of histone demethylases (KDM4B/ 
E/F). An unexpected finding that attracted our attention was the 
evident activation of the DUX4-driven zygotic program in the 
shETV4 as well as the shETV5 cells, the same program shown to 
be induced by DUX4 in the FSHD atrophic muscles (34, 35). We 
identified 33 upregulated members of the DUX4 pathway, includ-
ing DUX4, ZSCAN4, LEUTX, CCNA1, and the PRAME, TRIM, and 
MBD3L families (Figure 7D). We validated by RT-PCR a represen-
tative selection of genes from each of the 4 pathways (Figure 8).
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conduct the following experiments with 
ETV5, as it appears to be more abundant 
than ETV4 in SYO-1 cells, and also for the 
availability of a specific antibody that effi-
ciently pulls down ETV5. To explore ETV5-
E2F1 interactions, we performed ETV5 
and E2F1 pull-downs in SYO-1 cells and 
re-immunoprecipitated the former with a 
specific E2F1 antibody (Supplemental Fig-
ure 9A) and the latter with anti-ETV5 anti-
body (Supplemental Figure 9B). In these 
assays, we failed to detect a direct associ-
ation between ETV5 and E2F1. We then 
asked whether ETV5 directly regulated 
E2F1 and searched for potential ETV5 bind-
ing sites on the E2F1 locus. We looked for 
motifs that fit within the (A/C)GGA(A/T)
GT module (63, 64). Sequence analysis 
of the E2F1 gene (NCBI Ensembl; http://
useast.ensembl.org/Homo_sapiens/Gene/
Summary) extending 10 kb upstream and 
downstream of the transcriptional start site 
(TSS) identified a candidate ETV5 binding 
motif, AGGAAGT, situated approximately 
1 kb upstream of the TSS (Figure 10A).
DUX4 is expressed between the 
2-cell and the 4-cell embryonic stage, 
after which it is tightly silenced through-
out development. Elegant studies have 
shown that the chromatin assembly fac-
tor 1A/B (CHAF1A/B) complex is a major 
chromatin repressive complex that keeps 
the DUX4 gene in a silenced state (65). 
In another study, CHAF1A/B block was 
described as essential to DUX4 activation 
of the zygotic genome, and knockdown 
of either CHAF1A or CHAF1B abrogat-
ed DUX4 function (34). CHAF1A and 
CHAF1B play a crucial role in chromatin 
assembly during DNA replication and 
DNA repair, and they are regulated by 
Rb-E2F (61, 62). Moreover, transcription 
of CHAF1A and CHAF1B was downregu-
lated in the shETV4/5 SS cells (Figure 7C 
and Figure 8). Coimmunoprecipitation 
experiments in SYO-1 cells showed that 
CHAF1A exists in a complex with CHAF1B 
but does not interact with either ETV5 or 
E2F1 (Supplemental Figure 9, C and D). To 
examine E2F1 behavior in SYO-1 cells, we 
chose two of its established target genes, 
CCNE2 and CHAF1B. Our search for E2F1 binding motifs that fit 
the TTT(C/G)(C/G)CG(C/G) sequence (66) identified 1 potential 
site in the proximity of the CCNE2 TSS (Figure 10D), and 1 site 
located approximately 2.9 kb downstream of the CHAF1B TSS 
(Figure 10G). We performed chromatin immunoprecipitation 
(ChIP) in naive SYO-1 cells to measure ETV5 and E2F1 binding 
RNA-Seq screen are recognized as transcriptional targets of the 
(retinoblastoma) Rb-E2F complex (61, 62). To clarify the mecha-
nism by which ETV4/5 knockdown resulted in the downregulation 
of these genes, we inquired whether the ETV factors partnered 
with the E2F factors to promote their transcription. Since ETV4 
and ETV5 appeared to function similarly in SS cells, we chose to 
Figure 7. Analysis of the SS cell transcriptome upon ETV4 and ETV5 knockdown. Heatmaps of 
differentially expressed genes in SYO-1 cells expressing control, shETV4-2, and shETV5-2 vectors. 
Lanes a and b represent duplicate RNA samples. A selection of genes belonging to the cell cycle (A), 
transcription factors (B), chromatin (C), and DUX4 pathways (D) is shown.
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These findings strongly suggest that ETV4 and ETV5 are 
active modulators of the E2F1 pathway in SS cells, and they fit a 
functional model (Figure 10J) where autocrine FGF/FGFR sig-
naling initiated by SS18-SSX activates ETV4 and ETV5. The 
two factors trigger E2F and promote cell cycle progression and 
CHAF1A/B expression, leading to suppression of the DUX4 pro-
gram. ETV4 or ETV5 depletion results in reversal of this oncogen-
ic axis, DUX4 activation, and cell death.
Discussion
In the present report we reveal the prevalent expression of the 
oncogenic ETS factors ETV4 and ETV5 in synovial sarcoma 
tumors, and their key role as drivers of the cancer. In addition, we 
have uncovered a regulation of the DUX4 pathway by ETV4/5. 
Importantly, DUX4 activation led to cell death, thus opening a 
potential therapeutic path for SS.
Synovial sarcoma, like other mesenchymal cancers, diverts 
normal developmental pathways to promote its own initiation. 
FGFR signaling is such a pathway. Interestingly, in the trans-
genic SS models, FGFR1, FGFR2, and FGFR3 each appear to 
contribute to tumor formation. This finding was not surprising 
since SS arises in mesenchymal stem cells (MSCs) (67) that are 
capable of differentiating into multiple lineages, including bone, 
to the 3 genomic sites (Figure 10, A, D, and G). qPCR analysis 
showed significant occupancy of the specified regions in com-
parison with negative IgG controls (Figure 10B and lanes 1 and 
2 in Figure 10, E and H). Importantly, E2F1-ChIP conducted in 
shETV5-2–transduced SYO-1 cells showed a significant decrease 
in E2F1 binding to CCNE2 and CHAF1B relative to cells transduc-
ed with control (non-target) vector (lanes 3 and 4 in Figure 10, E 
and H). To verify whether the 3 binding regions drive endogenous 
transcription in SS cells, we subcloned the 3 genomic sequenc-
es shown in the diagrams in Figure 10, A, D, and G, in the PGL3 
luciferase reporter vector (a gift from Agata Levay, University of 
Miami). The generated vectors were PG-E2F1, PG-CCNE2, and 
PG-CHAF1B, respectively. When tested in a luciferase reporter 
assay, all 3 regions appeared to drive endogenous transcription 
(lane 1 in Figure 10, C, F, and I). To ascertain whether the putative 
ETV5 and E2F1 binding motifs described above are required for 
transcription, we deleted the 3 motifs (underlined sequences in 
Figure 10, A, D, and G) from the cloned regions, and the deletion 
mutants thus created (PG-dlE2F1, PG-dlCCNE2, PG-dlCHAF1B) 
were tested for driving transcription. Results from reporter assays 
showed that removing any 1 of the 3 motifs led to significant 
attenuation of the luciferase activity driven by their respective 
unmutated regions (lane 2 in Figure 10, C, F, and I).
Figure 8. Validation of the SS cell transcrip-
tome upon ETV4 and ETV5 knockdown. RT-PCR 
of the indicated targets in SYO-1 cells. GAPDH 
served as input control. RT-PCR was performed 
on 2 independent RNA samples (a and b) of 
control, shETV4-2–expressing, and shETV5-2–
expressing cells. Numbers represent band inten-
sities relative to control. Band intensities were 
calibrated with GAPDH; their measurement and 
the PCR primers used are described in Methods 
(Statistics) and Supplemental Methods.
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three tightly regulated FGFR receptors that are master control-
lers of bone and nervous system development (9, 10, 70) are like-
ly epigenetic targets of SS18-SSX (6). Since the human SS tumors 
express at least two of the three receptors, a selective inhibitor 
that blocks FGFR1–3 would in principle have an optimal effect in 
SS patients. Although in specific developmental settings such as 
lung branching, FGFR class dictates mediation of proliferation 
versus differentiation (71), the diminished Ki67 signals in the 
fat, muscle, and neurons. Thus, the developmental pathways 
that specify such lineages, and of which FGFR1–FGFR3 are key 
components, are epigenetically activated in MSCs and ready to 
signal when required (68). One of the important functions of the 
SS18-SSX fusion is its ability to reprogram MSCs and activate the 
neurogenic and osteogenic lineages (6). SS18-SSX fulfills these 
tasks through recruitment to polycomb-silenced chromatin and 
disruption of polycomb complexes (3, 4, 69). Accordingly, the 
Figure 9. Intersection of ETV4/5 
and the DUX4 pathway in SS cells. 
(A) Immunoblots show expression 
of the designated proteins in SYO-1 
and HS-SY-II cells expressing control, 
shETV4-2, and shETV5-2. Numbers 
represent relative protein signals. 
Protein intensities were adjusted to 
actin as described in Statistics. (B) 
Immunoblots show ETV5 and DUX4 
levels in SYO-1 cells expressing shETV5 
and shDUX4 vectors. Numbers display 
relative band intensities compared with 
actin. (C) Bar graph compares effects 
of cotransduced shETV5 and shDUX4 
(shETV5-2–shDUX4-1; shETV5-2–
shDUX4-2), shETV5-2, and control 
vectors on SYO-1 cell growth. Growth was 
measured by absorbance at 570 nm. The 
10 overlaid dots in each graph represent 
independent values from 2 SRB assays 
performed in 5 replicates. Error bars 
indicate SEM. P values compare mean 
absorbance between the shETV5 groups 
and the control group (*P < 0.0003), and 
between the shETV5-shDUX4 groups 
and the shETV5-control group (**P < 
0.00001). (D and E) Fold growth of SYO-1 
and HS-SY-II cells expressing lentiviral 
DUX4 over uninduced cells. Time points 
indicate days after DUX4 induction with 1 
μg/mL doxycycline. The 20 overlaid dots 
in every graph represent values from 2 
SRB assays performed in 10 replicates 
each. Error bars indicate SEM. P values 
compare mean growth on day 2 and day 
3 against average growth on day 1. *P < 
0.00001. (F) RT-PCR of gene targets in 
SYO-1 cells expressing inducible DUX4. 
Results are shown from 2 independent 
experiments (Exp. 1 and 2), compar-
ing induced with uninduced cells. DX, 
doxycycline. Numbers represent ratios of 
band intensity in induced over uninduced 
cells. Measurements were adjusted 
using GAPDH signal as described in 
Statistics. PCR primers are described in 
Supplemental Methods. (G) Immunoblot 
shows proteins activated upon DUX4 
induction (+DX) in SYO-1 and HS-SY-II 
cells. Actin is loading control. ANOVA F 
ratios and corresponding P values shown 
on top of the graphs in C–E demonstrate 
significant variation of means among 
the 5 and 3 groups, respectively.
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Figure 10. ETV5 and E2F1 genomic 
binding in SS cells. (A, D, and G) 
Diagrams display the sequence and 
location of the putative binding motifs 
(green) of ETV5 on the E2F1 gene, and 
of E2F1 on the CCNE2 and CHAF1B 
genes. The diagrams also delineate the 
regions selected for qPCR amplification 
and subcloning in the PGL3 reporter 
vector. (B, E, and H) Bar graphs show 
ETV5 binding to E2F1 (B) and E2F1 
binding to CCNE2 and CHAF1B genes 
(E and H). Dots (12 per group in B and 
6 per group in E and H) represent 
values from 2 independent ChIP-qPCR 
experiments. IgG served as background 
control. IgG binding and ETV5 or E2F1 
binding were quantified as percentage 
of input chromatin. Error bars indicate 
SEM. P values (*P ≤ 0.00009; **P < 
0.00001; ***P < 0.00001) compare 
ΔCt averages of ETV5 or E2F1 antibody 
versus IgG in naive cells and compare 
ΔCt averages of ETV5 or E2F1 binding 
in shETV5-expressing cells versus 
control (TRC2) cells. The PCR primers 
used are described in Supplemental 
Methods. (C, F, and I) Box plots demon-
strate endogenous transcriptional 
activity measured by luminescence 
(RLU) and driven by the binding 
regions of ETV5 (PG-E2F1, C) and E2F1 
(PG-CCNE2, F; and PG-CHAF1B, I), 
subcloned in PGL3. The PG-dlE2F1, 
PG-dlCCNE2, and PG-dlCHAF1B lanes 
show transcriptional activity of the 3 
regions lacking the binding motifs. The 
deleted sequences are underlined on 
the respective diagrams. The 10 dots in 
each lane represent individual values 
from 2 independent assays performed 
in 5 replicates. Crossbars indicate the 
mean, and error bars indicate SEM. P 
values were measured by comparison 
of the average of each PG-dl group with 
that of the corresponding PG vector. 
*P < 0.00001. (J) Model for the ETV4/5 
pathway in SS cells.
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state (65). Interestingly, most of the DUX4 repeat silencers are 
known E2F1 targets (61). Thus, their global downregulation in the 
shETV4/5 cells appears to be a result of E2F1 suppression. We 
focused our interest on the CHAF1A/B complex, as it was iden-
tified as a vital participant in DUX4 repression during embryonic 
development and in somatic cells. According to previous stud-
ies, CHAF1A/B inhibition alone could drive the global activation 
of DUX4 and its pathway (34, 65). Notably, we found that E2F1 
binding to the CHAF1B locus was significantly reduced in SS cells 
depleted of ETV5. The MBD3L (methyl-CpG binding domain pro-
tein 3–like) proteins are chromatin regulators that act as antago-
nists to NuRD-mediated silencing of the D4Z4 array (65). Thus, 
by directly activating the MBD3L family and the histone H3K9 
demethylase KDM4E, DUX4 would ensure a permanent state of 
derepressed chromatin, and so create a positive-feedback loop for 
its own expression when ETV4 or ETV5 function is lost.
DUX4 expression in FSHD muscles activates a gene signature 
similar to that of the zygotic stage. Differentiated muscle cells 
seem to be intolerant to aberrant embryonic programs, hence their 
atrophy. However, the mechanism underlying this process is still 
unclear. Several studies addressing the question of DUX4 toxicity 
in somatic cells have presented a variety of mechanisms, such as 
activation of antiviral response, dsRNA and protein aggregation, 
p53, p21 (CDKN1A), and MYC-dependent induction of EGR1, 
among others. It is currently thought that more than one death- 
inducing pathway is involved in mediating DUX4 effects (35, 59, 
60, 75). In our systems, ETV4/5 knockdown and DUX4 both lead 
to CDKN1A and EGR1 stimulation and cell death, and through this 
process, derepressed DUX4 likely compounds the cell cycle arrest 
caused by E2F1 suppression. Notably, a previous study has report-
ed on EGR1 repression by the SS18-SSX fusion in SS cells (76). Fur-
ther investigations will clarify whether a link exists between the 
several regulators that appear to converge on EGR1 in SS.
The SYO-1 and HS-SY-II cells carry the SS18-SSX2 and SS18-
SSX1 translocations, respectively. The 2 fusions represent the most 
frequent rearrangements in SS. Therefore, the biological findings 
in the 2 cell lines presented in these studies are of general rele-
vance to SS. Uncovering the tumorigenic axis that links FGFR sig-
naling to the ETV4/5 factors and the DUX4 program in SS carries 
wide significance. In addition to demonstrating the crucial role 
FGFR signaling plays in SS development, we have identified ETV4 
and ETV5 as drivers of the cancer, and potential targets for future 
SS therapies. Finally, the surprising finding that DUX4 appears to 
act as a tumor suppressor in this sarcoma is contrary to the recent 
discovery that DUX4 functions as an oncogene in several malig-
nancies (43), more particularly by converting CIC to an activator 
of the ETV4/5 oncogenes in CDS. With these opposite effects, we 
could conjecture that the mesenchymal progenitor background of 
SS tumors is a likely factor in influencing DUX4 behavior. Further 
mechanistic studies are needed to clarify this important point.
Altogether, our studies have uncovered a pathogenic link 
between FGFR signaling, ETV4/5, and the embryonic DUX4 
pathway in SS. In addition to FGFR inhibition and ETV4/5 block, 
these findings highlight DUX4 activation by specific epigenetic 
modulators as an additional tier for targeting SS and other human 
cancers in which these pathways are active, and which would thus 
benefit from DUX4-induced atrophy.
BGJ398-treated tumors indicate that FGFR signaling generally 
functions as a proliferation pathway in SS.
Our results show that expression of ETV4 and ETV5 is reg-
ulated by FGFR signaling at the transcriptional level. Moreover, 
ETV4 and ETV5 synchronized activation in the mouse and human 
SS tumors clearly suggests that the two factors are coregulated. In 
development, ETV4 and ETV5 are often coexpressed, while ETV1 
appears to be differently regulated (30). This might explain the 
apparent increase in ETV5 levels in the shFGFR1 and shFGFR3 
cells (Figure 4, A and E), as it points to a likely compensation by 
ETV5-positive regulators upon ETV4 attenuation. This scenar-
io is particularly pertinent in the shFGFR1/3 cells where FGFR2 
signaling is still intact and capable of promoting ETV5 expression. 
Importantly, the extensive overlap in the individual transcription 
programs induced by ETV4 and ETV5 indicates analogous func-
tions executed by both factors in SS. Nevertheless, the presence of 
ETV4 and ETV5 appears to be essential, since loss of either com-
ponent leads to significant growth arrest and inability to initiate 
tumor formation. Thus, each factor constitutes a potential thera-
peutic target for SS in its own right, but given apparent feedback 
mechanisms, it is safe to state that a therapy regimen that com-
pletely incapacitates both factors will be needed to maximize inhi-
bition of SS cell growth.
In CDS tumors, ETV4/5 upregulation occurs by direct binding 
of CIC-DUX4 to the gene promoters. Conversely, our data have 
demonstrated that ETV4/5 derepression in SS is likely caused by 
lack of CIC binding due to FGFR/ERK signaling and undetectable 
ATXN1/ATXN1L, two events that are known to destabilize the 
CIC repressor complex. Further studies are needed to understand 
the details of this mechanism.
The coordinated downregulation of ERK1/2, DUSP6, and 
SPRY4 by BGJ398 is reminiscent of the oncogenic ERK-ETV5-
DUSP6/SPRY2 negative-feedback loop previously discovered as a 
driver of acute lymphocytic leukemia and a promoter of drug resis-
tance (72). Our results indicate that an equivalent loop is located 
downstream of FGFR in SS cells. A recent report describes a sim-
ilar mechanism where DUSP6 inhibition helps degrade the CIC-
DUX4 oncoprotein by promoting CIC phosphorylation through 
MAPK-ERK activation (73). These findings suggest that targeting 
of DUSP6, though unintuitive, constitutes an appropriate addition 
or alternative for treating resistant SS tumors.
Downregulation of cell cycle and DNA repair mediators by 
ETV4 and ETV5 knockdown is consistent with the decrease in the 
proliferation marker Ki67 in the SS tumors treated with BGJ398. 
Importantly, it suggests that in SS, FGFR signaling controls prolif-
eration via ETV4/5. ETV4 has previously been linked to cell cycle 
regulation by its promotion of cyclin D1 expression in pancreat-
ic tumors (74). However, cyclin D1 was noticeably absent in our 
RNA-Seq screens, indicating that cell cycle regulation by the ETV 
factors is context specific. Moreover, the RNA-Seq, ETV5-ChIP, 
and endogenous reporter activity results indicate that cell cycle 
regulation by these factors in our systems likely occurs at the E2F 
level, thus explaining the downregulation of numerous E2F targets 
upon ETV4/5 depletion.
FSHD is an epigenetic disease, and a variety of chromatin 
silencers, such as CHAF1A/B, CBX1, EZH2, DNMT1, UHRF, and 
RBBP7, keep the D4Z4 repeats and DUX4 in a heterochromatic 
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In the RT-qPCR graphs, individual Ct (threshold cycle, also known 
as Cq or ΔR) values were normalized against GAPDH average Ct, and 
SDs between 2 experimental groups were derived from average ΔΔCt. 
Fold change was calculated as FC = 2–ΔΔCt. In the ChIP-qPCR graphs, 
the average Ct of input chromatin was adjusted to 2% of total chroma-
tin. ΔCts of the antibody were adjusted to the new average Ct of the 
input. Percentage input of individual antibody ΔCts was calculated as 
100 × 2ΔCt. P values were derived from SDs based on average ΔCts of 
experimental groups.
Intensities of PCR products (RT-PCR) and protein bands (immu-
noblots) were measured using ImageJ software (NIH) as follows: 
Background intensity was subtracted from absolute numbers, and 
then the average intensity of the respective loading controls — actin 
lanes in immunoblots and GAPDH lanes in RT-PCR gels — was calcu-
lated. Ratios of individual DNA or protein band intensities over aver-
age intensity of loading controls were measured, and fold change in 
gene transcription or protein expression was determined by compar-
ison of the ratios of band intensities with those of the experimental 
controls (adjusted to 1).
Study approval. The mouse studies were approved by the Insti-
tutional Animal Care and Use Committee at the University of Miami 
under protocol 19-184LF. Acquisition and analysis of human SS 
tumors were approved by University of Miami Hospital and Clinics 
under institutional research board protocol IRB 20121060.
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Methods
Cells. The SYO-1, HS-SY-II, and C2C12 cell lines were grown in 
DMEM supplemented with 10% FBS and 1× penicillin/strepto-
mycin (PS). The SYO-1 and HS-SY-II cells were provided by Marc 
Ladanyi (Memorial Sloan Kettering Cancer Center, New York, New 
York, USA), and the C2C12 cells were obtained from the American 
Type Culture Collection. The SS cells were authenticated through 
detection of the SS18-SSX fusion and grown on collagen-coated 
plates. The CDS-X1 cells (50) were maintained in RPMI 1640 
plus 10% FBS and 1× PS. The CDS-S2 cells (51) were maintained 
in DMEM/F-12–GlutaMAX (Gibco) plus 10% FBS. The CDS cells 
were authenticated by detection of the CIC-DUX4 fusion oncopro-
tein (Supplemental Figure 4B).
Genetic and xenograft mouse models. Mice were acquired, housed, 
and bred following an approved protocol (19-184LF) and rules set by 
the Institutional Animal Care and Use Committee at the University of 
Miami. The triple-knockout Fgfr1,2,3fl/fl mice were obtained from the 
Ornitz laboratory (Washington University) (46, 77, 78). The SSM2+ and 
Myf5-cre+ transgenic mice were obtained from the Capecchi labora-
tory (University of Utah). C57BL6/J mice used for the generation of 
Fgfr1fl/fl, Fgfr2fl/fl, and Fgfr3fl/fl (scheme not shown) and the NU/J mice 
were acquired from The Jackson Laboratory.
Genotyping of SSM2+ and Myf5-cre+ mice was performed as 
reported previously (7). Genotyping of Fgfr-floxed mice was con-
ducted by PCR as recommended by the Ornitz laboratory, with the 
GoTaq Flexi polymerase kit (Promega). The PCR conditions were 
as follows: 94°C for 3 minutes; 35 cycles of 94°C for 30 seconds and 
68°C for 3 minutes; 72°C for 5 minutes. The Fgfr primers (Ornitz 
laboratory) used for genotyping were: Fgfr1 forward, 5′-CCAGTA-
ACTGTACCAATGAGCTGTAAGCAT-3′; Fgfr1 reverse, 5′-TGC-
CCACCATGCTCCTGCTTCCTTCAGAGC-3′; Fgfr2 forward, 
5′-TTCCTGTTCGACTATAGGAGCAACAGGCGG-3′; Fgfr2 reverse, 
5′-GAGAGCAGGGTGCAAGAGGCGACCAGTCAG-3′; Fgfr3 for-
ward, 5′-GCTCCCTGTCCTGCCTCGTGTCTCCTAG-3′; Fgfr3 
reverse, 5′-AGGACAAATTGGTACCATACAACGTG-3′. Detection, 
counting, and measurement of tumors in the SM2, SMF1, SMF2, and 
SMF3 and in the BGJ398-treated SM2 mice were performed after 
euthanasia as previously described (7).
The xenograft SS models (BGJ398-treated tumors and shETV4/5 
tumors) were generated with subcutaneous injection of 8 × 106 SYO-1 
cells in 100 μL of 1× DPBS in Matrigel, in the right flank of NU/J mice. 
Visible tumors in all models were measured with a digital caliper.
Further information and experimental details are provided in 
Supplemental Methods.
Statistics. All graphs presented in the paper (dot plots, box plots, 
bar graphs) were drawn in RStudio, with the exception of the BGJ398 
dose-response curves in Figure 2, A and B, which were generated 
in Microsoft Excel.
In graphs where 3 or more experimental groups were included — 
namely those of Figure 4, B, D, and F; Figure 5, H–J; Figure 6, C, D, 
F, and G; Figure 9, C–E; and Supplemental Figure 2 — 1-way ANOVA 
was used for comparison of multiple means. P values calculated from 
ANOVA F ratios showing significant difference were followed by 
2-tailed t tests to compare means between 2 groups, as specified in the 
figure legends. The mean (average of values), SEM, and SD were cal-
culated in R or Excel. P values less than or equal to 0.05 were consid-
ered significant in all statistical tests used.
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